Edity Therapeutics ’s Post

Five years ago, I attended my first #ESMO, also here in #Barcelona. Back then we were thrilled to first introduce our team's groundbreaking work in #radiomics. At the time, the field was still relatively new, with immense potential to revolutionize how we evaluate #drug #efficacy in early drug development. Today, I'm incredibly proud of the journey Radiomics.bio and our amazing team have taken. We've been at the forefront of advancing #radiomics, transforming it from a theoretical concept into a powerful tool for evaluating drug efficacy in clinical trials. It's been a privilege to witness 1) the uptake in using a comprehensive and complete #tumor #burden analysis and #radiomics in #dose #selection and #optimization; and 2) the work we are doing to make it a #regulatory standard in the future. #ESMO24 #radiomics #oncology #drugdevelopment #innovation

𝐒𝐨𝐥𝐢𝐝 𝐁𝐢𝐨𝐬𝐜𝐢𝐞𝐧𝐜𝐞𝐬 & 𝐀𝐫𝐦𝐚𝐭𝐮𝐬 𝐁𝐢𝐨 𝐏𝐚𝐫𝐭𝐧𝐞𝐫 𝐟𝐨𝐫 𝐅𝐒𝐇𝐃 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 Solid Biosciences (Nasdaq: SLDB) Solid Biosciences has entered a non-exclusive worldwide license and collaboration agreement with Armatus Bio Armatus Bio, Inc. for the use of Solid’s proprietary capsid AAV-SLB101 in the development and commercialization of Armatus’ vectorized RNAi candidate to treat Facioscapulohumeral muscular dystrophy (FSHD). AAV-SLB101 has shown enhanced biodistribution and improved expression in muscle cells in preclinical studies. Under the agreement, Solid grants Armatus a non-exclusive worldwide license to utilize AAV-SLB101 for FSHD treatment and will provide Armatus with necessary materials, data, and know-how for development. Solid receives upfront payment, milestone payments, and royalties on net sales of products incorporating AAV-SLB101. Armatus will handle development and commercialization. Bo Cumbo Bo Cumbo, President and CEO of Solid Biosciences, stated, “Our transaction with Armatus Bio marks the beginning of a broad out-licensing of our capsid library. AAV-SLB101 is designed for enhanced biodistribution to skeletal muscle, aiming to improve efficacy and reduce toxicity of AAV-delivered gene therapies for muscular disorders. We're excited to expand AAV-SLB101’s use to FSHD through this agreement with Armatus Bio.” Armatus is developing ARM-201, a potential therapeutic for FSHD, which utilizes AAV-SLB101. ARM-201’s proprietary miRNA payload seeks to reduce DUX4, addressing muscle weakening and atrophy. Brian Price, Ph.D. Brian Price, Chief Technology Officer at Armatus Bio, commented, “The use of Solid’s unique AAV-SLB101 capsid will enable optimal patient dosing for our FSHD program. We're confident in the potential to reduce total AAV dose levels compared to first-generation capsids, supported by the strong safety profile demonstrated by AAV-SLB101 in Solid’s SGT-003 construct for the treatment of DMD. With this license, we are eager to advance ARM-201 as the lead candidate toward clinical evaluation." #agreement #partnership #clinicaltrials #collaboration #healthcare #safety #treatment #preclinical

🌟 Big News from Nucleai! We're thrilled to share a major milestone at Nucleai: the successful completion of our Series B extension, led by M Ventures , bringing our total funding to $60 million! This pivotal investment will enable us to further deploy our AI algorithms for the prospective enrollment of patients in clinical trials – a first in the field and a significant advancement in precision oncology. "M Ventures' investment boosts our ability to scale and deploy our spatial AI technology for patient enrollment in clinical trials and supports our work in the rapidly emerging areas of immunotherapies, antibody-drug conjugates, and bi-specifics," said Avi Veidman, Nucleai's CEO and Co-founder. 🙏 We're incredibly grateful for the trust and confidence our investors have placed in us. Together, we're set to transform the landscape of next-generation therapeutics. ➡️ Read the full announcement > https://bwnews.pr/3U5Jxgc #spatialbiomarkers #biomarkers #CDx #spatialbiology #digitalpathology #precisonmedicine #pressrelease #immunotherapy #precisiononcology

Another step towards revealing the power of spatial biology!

So excited to see what this outfit becomes! It really feels like we’re at a special time in pluripotent derived cell therapies where we have all the puzzle pieces, we just need to put them together! Looking forward to combining my experiences in developmental biology and PSC research, GMP translation and manufacture as well as ATMP Sweden and ATMP ecosystem synergies to work with amazing groups like the Cellerator to change the translation paradigm….its time to for disruption…. The time for pretty pictures is over, it’s time for patents, compliant raw/start materials, indication choice, health economy, market analysis, patient need, process and product controls, device, endpoints, startups, venture capital, manufacture….

Fast-track your in vivo preclinical immunotherapy development. MuScreen™ helps you rapidly identify the right markers and models for your preclinical programs improving efficiency and saving study time. Why screen your immunotherapy and immune modulating compounds with MuScreen? ✅Well-characterized syngeneic and tumor homograft (MuPrime™) models ✅Suitable for single agent and combination regimens ✅Cost effective (discount on shared control groups, cost of vehicle group covered) ✅ Time efficient (quickly identify responder models or markers) Don’t miss out. Our next screen is coming up soon. Registration closes January 12, 2024. Learn more ➡️ https://bit.ly/41INIQW #Syngeneic #InVivo #DrugDevelopment #Biotech #Bioscience

Launch of the Cellerator webpage - check it out to learn more about the Cellerator.

Artiva Biotherapeutics completed a successful $167 million IPO focused on advancing donor-derived cell therapy for autoimmune diseases, exceeding its financial target. The company aims to fund research on a treatment based on "natural killer" cells for conditions like lupus. This fundraising comes amidst growing interest in allogeneic cell therapies for autoimmune disorders, as they offer potential advantages over personalized cell treatments. With the rising optimism in the field of autoimmune cell therapy, companies like Artiva are exploring new avenues for impactful treatments. #celltherapy #autoimmune #IPO #biotech #innovation Read more here: https://lnkd.in/eCTGvEEm BioMedHack.com is your leading source for the latest news, breakthroughs, and insights in medicine, biohacking, and alternative medicine. Our mission is to help you live healthier and longer by bringing you cutting-edge information and expert advice. Follow us on Facebook, Instagram, and X.

🌟 Reflecting on the incredible advancements in biotech and medtech that are bringing hope to those affected by Leber's Hereditary Optic Neuropathy (LHON). As a talent partner in the industry, I'm privileged to witness firsthand the dedication of companies like GenSight Biologics and Neurophth Therapeutics / 纽福斯生物科技有限公司 Therapeutics, who are leading the charge in developing groundbreaking gene therapies for LHON. These therapies, such as LUMEVOQ (GS010) and NR082 (rAAV2-ND4), are not just treatments—they're beacons of hope for restoring vision and transforming lives. This cause is deeply personal to me. One of my closest friends lost his eyesight to LHON, igniting my passion to contribute to these life-changing advancements in biotech and medtech. Seeing the progress made gives me renewed purpose in my role as a talent partner, connecting talented individuals with companies driving innovation in ophthalmology and beyond. Let's continue pushing the boundaries of possibility and working towards a future where conditions like LHON no longer mean a loss of vision. Together, we can make a difference. #Biotech #Medtech #GeneTherapy #LHON #VisionRestoration #Innovation #MakingADifference

We’re in the news! This marks the beginning of an amazing new cooperation 👏👏👏 https://lnkd.in/gAp7wknC #RBCBioscience #ANGLE #DNA #RNA #CTCs #oncology #liquidbiopsy #precisionmedicine